MS SB2279

Adds seven substances to Schedule I controlled substances, including brorphine, metonitazene, zipeprol, and eutylone, classified as having no legitimate medical use and high potential for harm

Adds daridorexant and zuranolone to Schedule IV controlled substances, which have accepted medical uses and low abuse potential with limited dependence risk

Removes fenfluramine from Schedule IV controlled substances

Adds ganaxolone to Schedule V controlled substances with depressant effects on the central nervous system

Effective date: July 1, 2024